1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Vaccine Market by Technology, Disease, Route, End User & Type - Forecast to 2022

Vaccine Market: Forecast until 2022

  • August 2017
  • 206 pages
  • ID: 5073750
In this report:
In 2017, North America is expected to account for the largest share of ##.##% of the vaccines market for MMR. This regional segment is projected to reach USD ##.## million by 2022 from USD ##.## million in 2017, at a CAGR of ##.##%.
The intramuscular and subcutaneous administration segment is expected to account for the largest share of ##.##% of the global vaccines market in 2017 and is projected to register the highest CAGR of ##.##% during the forecast period.


Table of Contents

Search Inside

"Global vaccines market forecasted to grow at a CAGR (Compound annual growth rate) of 7.50 percent"

The vaccines market is forecasted to reach ~$49.3B by 2022 from ~$34.3B in 2017, at a compound annual growth rate (CAGR) of 7.50 percent. Growing prevalence of diseases, growing government and nongovernment funding for vaccine development, and rising investments by firms are driving the increase of the vaccines market. On the other hand, industry growth may be hindered due to the high cost of vaccine development and product recalls.

"Conjugate vaccines are anticipated to dominate the industry during the estimate period."

By technology, the vaccines market is split into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is forecasted to hold the biggest market share in 2017 and is also expected to register the highest CAGR (Compound annual growth rate) during the outlook period. Increasing prevalence of diseases and growing government investments are the top factors driving the increase of this segment.

"Monovalent vaccines segment forecasted to hold the largest market share in 2017."

Established on category, the vaccines market is divided into monovalent vaccines and multivalent vaccines. The monovalent segment is forecasted to dominate this industry with the biggest share due to rising investments by corporations to expand new vaccines.

"Pneumococcal disease segment is anticipated to witness high rise during the estimate period"

Established on the disease indication, the vaccines market is broken down into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus, rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is intended to account for the biggest share and is estimated to register the maximal rate during the outlook period. The rise in this industry segment can primarily be attributed to growing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease.

"Asia to witness high rise during the estimate period"

In 2017, North America (NA) is forecasted to account for the biggest share of the market succeeded by EU. Nevertheless, Asia continent is projected to register the highest compound annual growth rate (CAGR) during the outlook period. The important increase in this industry segment is assigned to the rising investments by firms in India (IN) and China (CN), increasing disposable income, increasing number of awareness programs and symposia, and increasing venture capital investments.

The primary interviews conducted for this business report can be categorized as follows:

• By Company category: Tier 1 - 36.0 percent; Tier 2 - 41.0 percent; Tier 3 - 23%.

• By Description : C-suite - 25.0 percent; D-level - 29.0 percent; Others - 46%.

• By Description : General Physicians - 38.0 percent; Purchase Managers - 29.0 percent; Medical Researchers - 33%.

• By Area: North America continent - 40.0 percent; Europe (EU) - 20.0 percent; Asia area - 33.0 percent; RoW - 7%.

List of firms decribed in the market research

• GlaxoSmithKline plc

• Pfizer, Incorporated

• Merck & Co., Incorporated

• Sanofi Pasteur SA

• CSL Limited

• Emergent BioSolutions, Incorporated

• Johnson & Johnson

• MedImmune, Limited liability company

Segment Research

The industry report offers an overview of the vaccines market. It aims at evaluating the market value and upcoming growth potential of this market across distinct segments including technology, category, disease indication, route of administration, end-user, and area. Moreover, the study also comprises a detailed competitive analysis of the top players in the sector together with their company descriptions, recent evolutions, and key industries strategies.

Main highlights

The analysis will facilitate the market top players/new sector entrants in this sector by providing them with the closest approximations of revenues for the global vaccines market and its sub-segments. This industry report will facilitate partners to comprehend the competitive landscape better and acquire business insights to position their businesses and help firms make suitable go-to-market approaches. The market research also benefits partners comprehend the pulse of the sector and offer them with info concerning main market drivers and alternatives.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Cholera Vaccines Market 2018-2022

Cholera Vaccines Sector: Worldwide Forecast until 2022

  • $ 2500
  • Industry report
  • December 2017
  • by Infiniti Research Limited

About Cholera VaccinesThe cholera vaccines market appears to be concentrated due to the presence of few established players. The major vendors in the market compete based on pricing and presence across ...

Global Pneumonia Therapeutics Market 2017-2021

Pneumonia Therapeutics Sector: Worldwide Forecast until 2021

  • $ 2500
  • Industry report
  • November 2017
  • by Infiniti Research Limited

About Pneumonia TherapeuticsPneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection. Pneumonia therapeutics market encompasses drugs and ...

Leprosy Global Clinical Trials Review, H2, 2017

Clinical Research in Leprosy in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Leprosy Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Leprosy Global Clinical Trials Review, H2, 2017" provides an overview of Leprosy clinical trials scenario. ...

Drug Analysis: TetraVax-DV $ 10000 January 2018

Drug Analysis: V180 $ 10000 January 2018

Drug Analysis: Dengvaxia $ 10000 January 2018


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on